Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb;12(2):558-580.
doi: 10.1016/j.apsb.2021.09.019. Epub 2021 Sep 25.

Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma

Affiliations
Review

Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma

Danyu Du et al. Acta Pharm Sin B. 2022 Feb.

Abstract

Hepatocellular carcinoma (HCC) is an aggressive human cancer with increasing incidence worldwide. Multiple efforts have been made to explore pharmaceutical therapies to treat HCC, such as targeted tyrosine kinase inhibitors, immune based therapies and combination of chemotherapy. However, limitations exist in current strategies including chemoresistance for instance. Tumor initiation and progression is driven by reprogramming of metabolism, in particular during HCC development. Recently, metabolic associated fatty liver disease (MAFLD), a reappraisal of new nomenclature for non-alcoholic fatty liver disease (NAFLD), indicates growing appreciation of metabolism in the pathogenesis of liver disease, including HCC, thereby suggesting new strategies by targeting abnormal metabolism for HCC treatment. In this review, we introduce directions by highlighting the metabolic targets in glucose, fatty acid, amino acid and glutamine metabolism, which are suitable for HCC pharmaceutical intervention. We also summarize and discuss current pharmaceutical agents and studies targeting deregulated metabolism during HCC treatment. Furthermore, opportunities and challenges in the discovery and development of HCC therapy targeting metabolism are discussed.

Keywords: 1,3-BPG, 1,3-bisphosphoglycerate; 2-DG, 2-deoxy-d-glucose; 3-BrPA, 3-bromopyruvic acid; ACC, acetyl-CoA carboxylase; ACLY, adenosine triphosphate (ATP) citrate lyase; ACS, acyl-CoA synthease; AKT, protein kinase B; AML, acute myeloblastic leukemia; AMPK, adenosine mono-phosphate-activated protein kinase; ASS1, argininosuccinate synthase 1; ATGL, adipose triacylglycerol lipase; CANA, canagliflozin; CPT, carnitine palmitoyl-transferase; CYP4, cytochrome P450s (CYPs) 4 family; Cancer therapy; DNL, de novo lipogenesis; EMT, epithelial-to-mesenchymal transition; ER, endoplasmic reticulum; ERK, extracellular-signal regulated kinase; FABP1, fatty acid binding protein 1; FASN, fatty acid synthase; FBP1, fructose-1,6-bisphosphatase 1; FFA, free fatty acid; Fatty acid β-oxidation; G6PD, glucose-6-phosphate dehydrogenase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GLS1, renal-type glutaminase; GLS2, liver-type glutaminase; GLUT1, glucose transporter 1; GOT1, glutamate oxaloacetate transaminase 1; Glutamine metabolism; Glycolysis; HCC, hepatocellular carcinoma; HIF-1α, hypoxia-inducible factor-1 alpha; HK, hexokinase; HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase; HSCs, hepatic stellate cells; Hepatocellular carcinoma; IDH2, isocitrate dehydrogenase 2; LCAD, long-chain acyl-CoA dehydrogenase; LDH, lactate dehydrogenase; LPL, lipid lipase; LXR, liver X receptor; MAFLD, metabolic associated fatty liver disease; MAGL, monoacyglycerol lipase; MCAD, medium-chain acyl-CoA dehydrogenase; MEs, malic enzymes; MMP9, matrix metallopeptidase 9; Metabolic dysregulation; NADPH, nicotinamide adenine nucleotide phosphate; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; OTC, ornithine transcarbamylase; PCK1, phosphoenolpyruvate carboxykinase 1; PFK1, phosphofructokinase 1; PGAM1, phosphoglycerate mutase 1; PGK1, phosphoglycerate kinase 1; PI3K, phosphoinositide 3-kinase; PKM2, pyruvate kinase M2; PPARα, peroxisome proliferator-activated receptor alpha; PPP, pentose phosphate pathway; Pentose phosphate pathway; ROS, reactive oxygen species; SCD1, stearoyl-CoA-desaturase 1; SGLT2, sodium-glucose cotransporter 2; SLC1A5/ASCT2, solute carrier family 1 member 5/alanine serine cysteine preferring transporter 2; SLC7A5/LAT1, solute carrier family 7 member 5/L-type amino acid transporter 1; SREBP1, sterol regulatory element-binding protein 1; TAGs, triacylglycerols; TCA cycle, tricarboxylic acid cycle; TKIs, tyrosine kinase inhibitors; TKT, transketolase; Tricarboxylic acid cycle; VEGFR, vascular endothelial growth factor receptor; WD-fed MC4R-KO, Western diet (WD)-fed melanocortin 4 receptor-deficient (MC4R-KO); WNT, wingless-type MMTV integration site family; mIDH, mutant IDH; mTOR, mammalian target of rapamycin.

PubMed Disclaimer

Figures

Image 1
Graphical abstract
Figure 1
Figure 1
Deregulated alterations of glucose metabolism in HCC. Deregulation of glucose metabolism during the initiation and progression of HCC has been early and well emphasized, including glucose transporters, enzymes and substrates in glycolysis, pentose phosphate pathway, gluconeogenesis and TCA cycle. Newly discovered functions of metabolic intermediates have also been referred, as histone lactylation by lactate. G6PC, glucose-6-phosphatase alpha; GPI, glucose-6-phosphate isomerase; HMGB1, high mobility group box 1; ALDOA, fructose-bisphosphate aldolase A; ENO1, enolase 1; PC, pyruvate carboxylase; PDHA1: pyruvate dehydrogenase A1; PHGDH, phosphoglycerate dehydrogenase; 6PGD, 6-phosphogluconate dehydrogenase; RPIA, ribose 5-phosphate isomerase A.
Figure 2
Figure 2
Deregulated alterations of fatty acid and cholesterol metabolism in HCC. Fatty acid and cholesterol metabolism function as other major catabolic pathways in the regulation of metabolism during HCC development. FATPs, fatty acid transport proteins; ACSL4, acyl-CoA synthetase long chain family member 4; HSL, hormone-sensitive lipase; SS, squalene synthase; SM, squalene monooxygenase; MUFA, monounsaturated fatty acid; DAG, diacylglycerol; MAG, monoacyglycerol.
Figure 3
Figure 3
Deregulated alterations of amino acid metabolism and glutamine metabolism in HCC. Genes and metabolic intermediates of the amino acid and glutamine metabolism are dysregulated in HCC, some of which can be regulated by aberrantly activated oncogenes and loss of tumor suppressors, such as mutant Kirsten rat sarcoma 2 viral oncogene homolog, aflatoxin B1 as well as noncoding RNAs. CPS1, carbamyl phosphate synthase 1; ARG1, arginase-1; GLUD, glutamate dehydrogenase; GSH, glutathione; ASNS, asparagine synthetase; ASL, argininosuccinate lyase.
Figure 4
Figure 4
Agents targeting metabolism in HCC. This figure lists all drugs or chemicals developed as potentials to treat HCC by targeting metabolism. Light blue and dark blue lines depict agents targeting metabolism in preclinical studies. Orange lines depict agents targeting metabolism in clinical studies. Brown lines depict repositioned drugs targeting metabolism in HCC.

Similar articles

Cited by

References

    1. Chen W., Zheng R., Baade P.D., Zhang S., Zeng H., Bray F., et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132. - PubMed
    1. Forner A., Reig M., Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–1314. - PubMed
    1. Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380:1450–1462. - PubMed
    1. Abou-Alfa G.K., Johnson P., Knox J.J., Capanu M., Davidenko I., Lacava J., et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA. 2010;304:2154–2160. - PubMed
    1. Qin S., Bai Y., Lim H.Y., Thongprasert S., Chao Y., Fan J., et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013;31:3501–3508. - PubMed
-